[
  {
    "ts": null,
    "headline": "Here's Why AbbVie (ABBV) Fell More Than Broader Market",
    "summary": "In the most recent trading session, AbbVie (ABBV) closed at $185.48, indicating a -2.82% shift from the previous trading day.",
    "url": "https://finnhub.io/api/news?id=c1780aed9de2b701b99c495fad318913d170b043c68b9333b13ca2115f2b5bc9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750196703,
      "headline": "Here's Why AbbVie (ABBV) Fell More Than Broader Market",
      "id": 135340445,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "In the most recent trading session, AbbVie (ABBV) closed at $185.48, indicating a -2.82% shift from the previous trading day.",
      "url": "https://finnhub.io/api/news?id=c1780aed9de2b701b99c495fad318913d170b043c68b9333b13ca2115f2b5bc9"
    }
  },
  {
    "ts": null,
    "headline": "Trump's big beautiful bill: What the pharma industry is watching",
    "summary": "Pharmaceutical stocks, including Pfizer (PFE), Johnson & Johnson (JNJ), Abbvie (ABBV), Novo Nordisk (NVO), and Astrazeneca (AZN), are falling after President Trump said tariffs on the industry are coming \"very soon.\" Chris Meekins, managing director and Washington health policy research analyst at Raymond James, joins Market Domination to discuss potential tariffs and explain how President Trump's tax bill could affect the pharmaceutical industry. To watch more expert insights and analysis on the latest market action, check out more Market Domination here.",
    "url": "https://finnhub.io/api/news?id=6248ba62415c0d98cf70db9a6829706b01cfd3a870c8f72a7fa03c8efc5898e5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750194995,
      "headline": "Trump's big beautiful bill: What the pharma industry is watching",
      "id": 135340446,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Pharmaceutical stocks, including Pfizer (PFE), Johnson & Johnson (JNJ), Abbvie (ABBV), Novo Nordisk (NVO), and Astrazeneca (AZN), are falling after President Trump said tariffs on the industry are coming \"very soon.\" Chris Meekins, managing director and Washington health policy research analyst at Raymond James, joins Market Domination to discuss potential tariffs and explain how President Trump's tax bill could affect the pharmaceutical industry. To watch more expert insights and analysis on the latest market action, check out more Market Domination here.",
      "url": "https://finnhub.io/api/news?id=6248ba62415c0d98cf70db9a6829706b01cfd3a870c8f72a7fa03c8efc5898e5"
    }
  },
  {
    "ts": null,
    "headline": "3 Dividend Growth Stocks To Buy and Hold Forever",
    "summary": "These three companies have a high 5-year dividend yield, providing long-term stability while maximizing income.",
    "url": "https://finnhub.io/api/news?id=1acc30a832df0e5dce4ad0800113eb40f9042a1dbfabb59a97340b2c1f747bff",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750188175,
      "headline": "3 Dividend Growth Stocks To Buy and Hold Forever",
      "id": 135340447,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "These three companies have a high 5-year dividend yield, providing long-term stability while maximizing income.",
      "url": "https://finnhub.io/api/news?id=1acc30a832df0e5dce4ad0800113eb40f9042a1dbfabb59a97340b2c1f747bff"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Inc. stock underperforms Tuesday when compared to competitors",
    "summary": "AbbVie Inc. stock underperforms Tuesday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=bc27b71031201e0856d871ee9ffc90c5fe44428d5f6b98ef11629275681bfd50",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750177860,
      "headline": "AbbVie Inc. stock underperforms Tuesday when compared to competitors",
      "id": 135354838,
      "image": "",
      "related": "ABBV",
      "source": "MarketWatch",
      "summary": "AbbVie Inc. stock underperforms Tuesday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=bc27b71031201e0856d871ee9ffc90c5fe44428d5f6b98ef11629275681bfd50"
    }
  },
  {
    "ts": null,
    "headline": "AMD extends gains, solar stocks plummet, pharma stocks",
    "summary": "Wealth host Brad Smith tracks today's top moving stocks and biggest market stories in this Market Minute. Advanced Micro Devices (AMD) stock extends its gains from Monday when Piper Sandler raised its price target for the company. Solar energy stocks, including Enphase (ENPH), First Solar (FSLR), and SolarEdge (SEDG), plummet as Senate Republicans consider phasing out clean energy tax credits by 2028. Pharmaceutical stocks, such as Eli Lilly (LLY), Pfizer (PFE), and Abbvie (ABBV), are under pressure as the Trump administration considers curbing direct-to-consumer drug advertising. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute.",
    "url": "https://finnhub.io/api/news?id=90631f694600db52342c8cb957af406f7d9a2700e514e3f3adc13df2cf440585",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750173499,
      "headline": "AMD extends gains, solar stocks plummet, pharma stocks",
      "id": 135327762,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Wealth host Brad Smith tracks today's top moving stocks and biggest market stories in this Market Minute. Advanced Micro Devices (AMD) stock extends its gains from Monday when Piper Sandler raised its price target for the company. Solar energy stocks, including Enphase (ENPH), First Solar (FSLR), and SolarEdge (SEDG), plummet as Senate Republicans consider phasing out clean energy tax credits by 2028. Pharmaceutical stocks, such as Eli Lilly (LLY), Pfizer (PFE), and Abbvie (ABBV), are under pressure as the Trump administration considers curbing direct-to-consumer drug advertising. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute.",
      "url": "https://finnhub.io/api/news?id=90631f694600db52342c8cb957af406f7d9a2700e514e3f3adc13df2cf440585"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie's Venclexta Misses Goal in Myelodysplastic Syndromes Study",
    "summary": "Venclexta fails to meet survival goals in ABBV's phase III MDS study, marking another clinical setback for the cancer drug.",
    "url": "https://finnhub.io/api/news?id=565b6dd6b0778bceaa4d42d2c9ed9de993d18a4215b1734b63d835f67d67d0fa",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750170600,
      "headline": "AbbVie's Venclexta Misses Goal in Myelodysplastic Syndromes Study",
      "id": 135328662,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Venclexta fails to meet survival goals in ABBV's phase III MDS study, marking another clinical setback for the cancer drug.",
      "url": "https://finnhub.io/api/news?id=565b6dd6b0778bceaa4d42d2c9ed9de993d18a4215b1734b63d835f67d67d0fa"
    }
  },
  {
    "ts": null,
    "headline": "RFK Jr. Plans Crackdown on Pharma Ads in Threat to $10 Billion Market",
    "summary": "(Bloomberg) -- The Trump administration is discussing policies that would make it harder and more expensive for pharmaceutical companies to advertise directly to patients, in a move that could disrupt more than $10 billion in annual ad spending.Most Read from BloombergSecurity Concerns Hit Some of the World’s ‘Most Livable Cities’As Part of a $45 Billion Push, ICE Prepares for a Vast Expansion of Detention SpaceAs American Architects Gather in Boston, Retrofits Are All the RageHow E-Scooters Con",
    "url": "https://finnhub.io/api/news?id=4f13bd1d807f814d194a94fbc1572d6fab61acd4f736c1a4a240b1ac0fe3a62d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750169552,
      "headline": "RFK Jr. Plans Crackdown on Pharma Ads in Threat to $10 Billion Market",
      "id": 135327459,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "(Bloomberg) -- The Trump administration is discussing policies that would make it harder and more expensive for pharmaceutical companies to advertise directly to patients, in a move that could disrupt more than $10 billion in annual ad spending.Most Read from BloombergSecurity Concerns Hit Some of the World’s ‘Most Livable Cities’As Part of a $45 Billion Push, ICE Prepares for a Vast Expansion of Detention SpaceAs American Architects Gather in Boston, Retrofits Are All the RageHow E-Scooters Con",
      "url": "https://finnhub.io/api/news?id=4f13bd1d807f814d194a94fbc1572d6fab61acd4f736c1a4a240b1ac0fe3a62d"
    }
  },
  {
    "ts": null,
    "headline": "Is AbbVie (ABBV) a Buy as Wall Street Analysts Look Optimistic?",
    "summary": "The average brokerage recommendation (ABR) for AbbVie (ABBV) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?",
    "url": "https://finnhub.io/api/news?id=6408c9ed22dc20bd35da9555155862c73ca2530de9a428b7658909e9b2a10055",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750167003,
      "headline": "Is AbbVie (ABBV) a Buy as Wall Street Analysts Look Optimistic?",
      "id": 135328666,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "The average brokerage recommendation (ABR) for AbbVie (ABBV) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?",
      "url": "https://finnhub.io/api/news?id=6408c9ed22dc20bd35da9555155862c73ca2530de9a428b7658909e9b2a10055"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie says Phase 3 Verona trial of venetoclax/azacitidine did not meet endpoint",
    "summary": "AbbVie (ABBV) announced the global Phase 3 Vevrona trial evaluating venetoclax in combination with azacitidine in the treatment of newly diagnosed higher-risk myelodysplastic syndrome did not meet the primary endpoint of overall survival with a hazard ratio of 0.908; stratified log-rank. No new safety signals were observed. Results from the Verona trial will be available in a future medical congress and/or publication. Any patients who received venetoclax in combination with azacitidine through",
    "url": "https://finnhub.io/api/news?id=6daa488ba9d31c43e7ddacb54a562a3e7dd14cc079de45b5d99d7193781935f3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750165538,
      "headline": "AbbVie says Phase 3 Verona trial of venetoclax/azacitidine did not meet endpoint",
      "id": 135327460,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (ABBV) announced the global Phase 3 Vevrona trial evaluating venetoclax in combination with azacitidine in the treatment of newly diagnosed higher-risk myelodysplastic syndrome did not meet the primary endpoint of overall survival with a hazard ratio of 0.908; stratified log-rank. No new safety signals were observed. Results from the Verona trial will be available in a future medical congress and/or publication. Any patients who received venetoclax in combination with azacitidine through",
      "url": "https://finnhub.io/api/news?id=6daa488ba9d31c43e7ddacb54a562a3e7dd14cc079de45b5d99d7193781935f3"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie's Diversification Strategy Cushions Venetoclax MDS Blow",
    "summary": "AbbVie's diversified pipeline, growth strategies, and 3.43% dividend yield make it a strong investment option despite challenges like pricing pressure.",
    "url": "https://finnhub.io/api/news?id=e6936f5d553c6a40c7d3c964cad19be05fc393428c40fde94eb416ddc810a466",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750142542,
      "headline": "AbbVie's Diversification Strategy Cushions Venetoclax MDS Blow",
      "id": 135325294,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1824400059/image_1824400059.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "AbbVie's diversified pipeline, growth strategies, and 3.43% dividend yield make it a strong investment option despite challenges like pricing pressure.",
      "url": "https://finnhub.io/api/news?id=e6936f5d553c6a40c7d3c964cad19be05fc393428c40fde94eb416ddc810a466"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie (ABBV) Pipeline Bolstered as FDA Approves Mavyret Label Expansion for Hepatitis C",
    "summary": "AbbVie Inc. (NYSE:ABBV) is one of the 12 best healthcare stocks to buy now. On June 12, the US Food and Drug Administration (FDA) approved the company’s Mavyret treatment label expansion. The approval makes the treatment the first antiviral therapy for people with Acute Hepatitis C Virus (HCV). The FDA agreed to a label expansion […]",
    "url": "https://finnhub.io/api/news?id=5e6031a16910ee3d0273ee92d17913cdb9762e3bdfe5a28bd3632ced401ddfee",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750141455,
      "headline": "AbbVie (ABBV) Pipeline Bolstered as FDA Approves Mavyret Label Expansion for Hepatitis C",
      "id": 135317016,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie Inc. (NYSE:ABBV) is one of the 12 best healthcare stocks to buy now. On June 12, the US Food and Drug Administration (FDA) approved the company’s Mavyret treatment label expansion. The approval makes the treatment the first antiviral therapy for people with Acute Hepatitis C Virus (HCV). The FDA agreed to a label expansion […]",
      "url": "https://finnhub.io/api/news?id=5e6031a16910ee3d0273ee92d17913cdb9762e3bdfe5a28bd3632ced401ddfee"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie, ADARx Pharmaceuticals Partner to Develop Next-Gen siRNA Therapeutics",
    "summary": "AbbVie Inc. (NYSE:ABBV) is one of the best stocks to buy for beginners now. In mid-May, AbbVie and ADARx Pharmaceuticals announced a collaboration and license option agreement. The partnership aims to develop small interfering RNA (siRNA) therapeutics across multiple disease areas, such as neuroscience, immunology, and oncology. siRNA molecules are a class of genetic medicines […]",
    "url": "https://finnhub.io/api/news?id=0753cf6f4421c4abf2dfd4b5a10f10983c55ea936d89a0c0e6c21ee18a7dc4dd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750141430,
      "headline": "AbbVie, ADARx Pharmaceuticals Partner to Develop Next-Gen siRNA Therapeutics",
      "id": 135317017,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie Inc. (NYSE:ABBV) is one of the best stocks to buy for beginners now. In mid-May, AbbVie and ADARx Pharmaceuticals announced a collaboration and license option agreement. The partnership aims to develop small interfering RNA (siRNA) therapeutics across multiple disease areas, such as neuroscience, immunology, and oncology. siRNA molecules are a class of genetic medicines […]",
      "url": "https://finnhub.io/api/news?id=0753cf6f4421c4abf2dfd4b5a10f10983c55ea936d89a0c0e6c21ee18a7dc4dd"
    }
  }
]